MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMSOUTH SAN FRANCISCO, Calif., ...

The emergence of novel pharmacotherapies, minimally-invasive procedures and gene-directed approaches shall fundamentally alter the Hypertrophic Cardiomyopathy therapeutic landscape. Amongst all ...

Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

Learn about sudden cardiac death risk in people with hypertrophic cardiomyopathy, including risk factors, prevention methods, ...

For patients with hypertrophic cardiomyopathy that doesn’t improve with standard therapy, surgery may be the next choice. In France, a new study was conducted to compare the incidence of in-hospital ...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Find out more about how coffee — and the caffeine it contains — may impact this genetic heart condition that causes the heart to pump less effectively.

Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UCSF study finds that Artificial Intelligence-enhanced ...

If you have hypertrophic cardiomyopathy (HCM), your heart struggles to work as well. This causes fatigue and other symptoms. Getting enough sleep is important for supporting your physical and mental ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. The Food and Drug Administration (FDA) has approved Camzyos ™ (mavacamten) for the treatment of adults with ...